Company news

DRI Healthcare Trust news in 2024

DRI Healthcare Trust's news releases, calls and decks from 2024, newest first.

View company

DRI Healthcare Trust Declares Special Unit Distribution

December 20, 2024

DRI Healthcare Trust Reports Third Quarter 2024 Results

November 6, 2024

DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for the Treatment of Hereditary Angioedema Plus an Equity Investment in KalVista Pharmaceuticals

November 4, 2024

DRI Healthcare Trust Announces Upsized US$631.6 Million Credit Facilities

November 1, 2024

DRI Healthcare Trust to Host Third Quarter Earnings Call and Webcast on November 7, 2024

October 11, 2024

DRI Healthcare Trust Announces Acquisition of Payment Streams based on the Cas9 Gene-Editing Technology for CASGEVY® (exagamglogene autotemcel)

October 3, 2024

DRI Healthcare Trust Reports Second Quarter 2024 Results

August 6, 2024

DRI Healthcare Trust and DRI Capital Inc. Announce Executive Changes

July 8, 2024

DRI Healthcare Trust to Host Second Quarter Earnings Call and Webcast on August 7, 2024

July 3, 2024

DRI Healthcare Trust Announces Acquisition of an Additional Royalty Interest in the Worldwide Sales of Xenpozyme® (olipudase alfa) for the Treatment of Acid Sphingomyelinase Deficiency

July 2, 2024

DRI Healthcare Trust Reports First Quarter 2024 Results

May 6, 2024

DRI Healthcare Trust Closes Previously Announced Refinancing of Preferred Securities

April 23, 2024

DRI Healthcare Trust to Host First Quarter Earnings Call and Webcast on May 7, 2024

April 16, 2024

DRI Healthcare Trust Announces Refinancing of Preferred Securities

April 15, 2024

DRI Healthcare Trust Announces Participation in Upcoming Investor Conferences

March 26, 2024

DRI Healthcare Trust Reports Fourth Quarter and Fiscal 2023 Results

February 28, 2024

DRI Healthcare Trust to Host Fourth Quarter and Full Year 2023 Earnings Call and Webcast on February 29, 2024

February 8, 2024

DRI Healthcare Trust Announces the Expansion of its Royalty Entitlement on the US Net Sales of Omidria®, Updates Deployment and CAGR Guidance

February 1, 2024

Decks in 2024